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AbstrAct
Ewing sarcoma (EwS) is an aggressive pediatric bone cancer in need of more 
effective therapies than currently available. Most research into novel targeted 
therapeutic approaches is focused on the fusion oncogene EWSR1-FLI1, which is the 
genetic hallmark of this disease. In this study, a broad range of 3,325 experimental 
compounds, among them FDA approved drugs and natural products, were screened 
for their effect on EwS cell viability depending on EWS-FLI1 expression. In a network-
based approach we integrated the results from drug perturbation screens and RNA 
sequencing, comparing EWS-FLI1-high (normal expression) with EWS-FLI1-low 
(knockdown) conditions, revealing novel interactions between compounds and EWS-
FLI1 associated biological processes. The top candidate list of druggable EWS-FLI1 
targets included genes involved in translation, histone modification, microtubule 
structure, topoisomerase activity as well as apoptosis regulation. We confirmed our 
in silico results using viability and apoptosis assays, underlining the applicability 
of our integrative and systemic approach. We identified differential sensitivities of 
Ewing sarcoma cells to BCL-2 family inhibitors dependent on the EWS-FLI1 regulome 
including altered MCL-1 expression and subcellular localization. This study facilitates 
the selection of effective targeted approaches for future combinatorial therapies of 
patients suffering from Ewing sarcoma.
www.oncotarget.com                               Oncotarget, 2018, Vol. 9, (No. 57), pp: 31018-31031
           Research Paper
Oncotarget31019www.oncotarget.com
IntroductIon 
Ewing sarcoma (EwS) belongs to a family of highly 
malignant primary tumors, which arise in bone and soft 
tissues, affecting children and adolescents [1]. The genetic 
hallmark of EwS is the presence of the chromosomal 
translocation t(11;22) (q24;q12) that generates the EWS-
FLI1 fusion gene [2]. The resulting fusion protein, which 
is found in 85% of EwS patients, contains the amino 
terminal domain of the transcriptional activator EWS, and 
the carboxyl terminal domain of the DNA binding protein 
FLI1. EWS-FLI1 is an aberrant transcription factor that 
both activates and represses expression of hundreds of 
genes, many of them being crucial for EwS pathogenesis. 
EWS-FLI1 has been characterized as the “Achilles’ heel” 
of EwS and an ideal therapeutic target [3, 4]. Recently, the 
small molecule YK-4-279 was shown to interfere directly 
with the EWS-FLI1 activity by blocking its interaction 
with RNA helicase A. An analog of YK-4-279 has now 
entered clinical trials (NCT02657005) [5]. Exploiting 
the downstream network of EWS-FLI1 is crucial for the 
discovery of alternative inhibitory scaffolds. 
In this study we used a network-based integrative 
analysis platform to investigate druggable target gene 
spectra of EWS-FLI1. Among the top druggable target hits 
we found compelling evidence for EWS-FLI1-dependent 
sensitivities to BCL-2 family member inhibitors. 
Depending on their BCL-2 homology (BH) domains and 
function, the BCL-2 family of proteins can be classified 
into three different groups. The pro-apoptototic BCL-2 
family members, BAX and BAK, anti-apoptotic 
memebers BCL-2, MCL-1, BCL-X, BCL-W and BFL-1/
A1. The third class of BCL-2 family members consists 
of the so-called BH-sensitizers BAD, BIK, NOXA, 
BMF, Harakiri and PUMA [6]. The balance of pro- and 
antiapoptotic BCL-2 proteins is crucial for cell survival 
and commonly exploited by cancer cells, which due 
to their exaggerated metabolism, oncogenic stress and 
cancer therapy are more primed for cell death [6–8]. Via 
alternative splicing the long isoform (L) of anti-apopototic 
BCL-2 family member proteins can be shortened into a 
pro-apoptotic version (S), such as for MCL-1 (L/S) and 
BCL-X (L/S), further influencing the balance between 
pro- and antiapoptotic proteins within a cell [7]. Given 
the importance of BCL-2 proteins for oncogenic cell 
survival, several BCL-2 family inhibitors, so called BH3 
mimetics, have been developed. Obatoclax (GX-15-070) 
binds to a broad range of BCL-2 family proteins with low 
affinity, in a BAX/BAK independent manner. ABT-737 
and navitoclax (ABT-263) more specifically inhibit BCL-
2 and BCL-X(L) [8] and exhibit greater bioavailability and 
improved clinical responses. Resistance mechanisms via 
MCL-1, however, have frequently been reported for these 
BH3 mimetics [8, 9]. Here, we report major differences of 
EwS cells in the response to obatoclax and navitoclax or 
ABT-737, depending on the EWS-FLI1 expression status. 
Investigation of BCL-2 family member protein expression 
and their subcellular localization revealed an EWS-FLI1 
dependent effect on MCL-1(L) to be at least partially 
responsible for the differential sensitivities of EwS cells 
towards navitoclax treatment. The results confirmed our 
systematic approach and yielded novel insights into the 
druggable interactome of EwS. 
rEsuLts 
Establishing criteria for hit selection
In this study, we performed a high-throughput 
phenotypic screen of 3,325 FDA-approved and 
experimental compounds in an EwS cell line, A673/TR/
shEF, where EWS-FLI1 expression can be modulated 
from high to low via doxycycline (dox)-inducible shRNA 
expression [10–12] (Workflow: Figure 1A). To identify 
selective anti-proliferative compounds effective under 
EWS-FLI1-high and -low conditions, cells were either 
cultured without dox and exposed to drugs for 72 h (EWS-
FLI1-high condition), or pre-treated with dox for 24 hours 
and then exposed to drugs for 72 hours in the presence of 
dox (EWS-FLI1-low condition) (Supplementary Figure 1A, 
Supplementary Tables 1 and 2). To gain insights into 
the target spectra of all screened compounds (1,515 
compounds with reported targets), we used the chemical 
protein interaction resources ChEMBL [13] and STITCH 
[14] (Supplementary Table 3). To more specifically study 
compounds interfering with EWS-FLI1 activity, we 
furthermore grouped the tested compounds into (i) those 
that present increased efficacy in EWS-FLI1-high cells 
and (ii) those that are more potent in EWS-FLI1-low 
cells. The criterion for assessing increased efficacy was a 
decrease in viability at a single concentration by at least 
two-fold for EWS-FLI1-high cells versus EWS-FLI1-low 
cells for the group (i) and vice versa for the group (ii) (see 
Materials and Methods & Supplementary Table 1). A third 
group of compounds reduced cell viability independent of 
EWS-FLI1 expression, likely by EWS-FLI1-independent 
mechanisms.
compounds that are more effective in EWs-
FLI1-high than in EWs-FLI1-low Ews cells 
We found 70 out of the 3,325 unique compounds 
to be more effective in EWS-FLI1-high cells, of them 47 
are already FDA approved (Supplementary Table 4). After 
acquiring the known targets of all the tested compounds, 
we confirmed that the hit selection was not biased towards 
the number of compound targets (compound promiscuity). 
The median number of targets corresponding to the 70 hits 
was 4, while by comparison 5 targets per compound were 
represented in the group of non-hits (Figure 1B).
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To gain further insight into the mechanisms of 
action for the selected compound hit list, we extracted 
(i) the genes that were exclusively targeted by the hit 
compounds and (ii) the genes that were significantly 
enriched targets in the list of hit compounds (Fisher’s 
exact test, q-value < 0.05). The two gene sets were 
combined to form a single candidate gene list for further 
analysis (Supplementary Table 5). We applied functional 
annotation gene enrichment using the DAVID tool suite 
[15], more specifically the Gene Ontology branches 
“Biological process” and “Molecular function”, as well as 
the KEGG pathway [16] database to study the assigned 
functions of our candidate gene list [17]. 
The druggable candidate gene list contained 
genes associated with critical cellular functions such as 
translation (anisomycin), histone modification (HDAC 
inhibitors belinostat, vorinostat, mocetinostat and CUDC-
101), microtubule structure (vincristine, vinblastine and 
Figure 1: compound and target discovery. (A) Schematic representation of our systematic approach developed to identify effective 
compounds and biological vulnerabilities in EwS. (b) Distribution of targets per compound. Left: Target distribution of the effective 
compounds (hits). The effective compounds with known targets included 23 experimental and 47 FDA approved compounds. FDA 
approved drugs cover the major percentage of the 70 hits (67%), and the median of the reported targets is 4. Right: Target distribution of the 
non-effective compounds. The median of targets for the non-effective compounds (with at least one known target) is 5 and the list includes 
27% (394) FDA approved compounds. 
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taxol), topoisomerase activity (irinotecan, topotecan, 
idarubicin and doxorubicin) as well as apoptosis regulation 
(cytarabine, bortezomib, gambogic acid and obatoclax 
mesylate) (Figure 2A). Furthermore, members of the ABC 
transporter family (e.g. ABCC10, ABCC1, ABCG2 and 
ABCB8), as well as transcription factors such as ATF3, 
ILF3 and HIF-1a were among the candidate gene sets 
(Figure 2B and Supplementary Table 6). 
To further annotate our candidate set of druggable 
genes in EwS to EWS-FLI1 expression, we first integrated 
previously published RNA-seq data from EWS-FLI1-high 
and -low EwS cells into our analysis [10]. A minimum 
of 1-fold change in gene expression upon EWS-FLI1 
modulation (72 h dox treatment) and a p-value cutoff 
after False Discovery Rate (FDR) adjustment for multiple 
testing of 0.01 was accepted for further analysis. Next, 
we combined this information with previously published 
ChIP-seq-derived EWS-FLI1 direct targets [18]. Using 
the STRING database [19], interactions between effective 
compounds and EWS-FLI1 direct and indirect targets 
were mapped (Figure 2B). Thereby, we found so far 
unrecognized interactions, such as between HDAC inhibitor 
hits and the EWS-FLI1 regulated genes EGFR, MEFC2, 
RUNX2 and CCND1. A number of compounds were also 
found to interfere with EWS-FLI1 regulated genes, which 
are involved in translation and apoptosis. In particular, 
multiple members of the ribosomal protein family, 
BIRC3, NLRP1, GSN and NGFR were affected by EWS-
FLI1 modulation and chemical inhibition (Figure 2B). 
A list of the compound targets and respective RNA-seq and 
ChIP-seq-derived annotation is provided in Supplementary 
Table 3.
compounds that are more effective in EWs-
FLI1-low than in EWs-FLI1-high Ews cells 
We also tested the efficacy of compounds in the 
EWS-FLI1-low state. Recently, it was shown that EwS 
cells with lower levels of EWS-FLI1 exhibit enhanced 
migratory features and are more prone to metastasize [20]. 
The investigation of drugs which are effective in EWS-
FLI1-low cells is therefore of interest for combinatorial 
approaches to prevent metastasis formation in EwS and to 
circumvent resistance to EWS-FLI1 targeted therapy due 
to EWS-FLI1-low EwS cells. For validation of the test 
system, we confirmed differential sensitivity of EwS cells 
to the EWS-FLI1 targeting compound YK-2-479 under 
EWS-FLI1-high versus -low conditions (Supplementary 
Figure 1B). From our screen, eight compounds fulfilled 
the hit criteria in the EWS-FLI1-low state, among them 
one FDA approved anti-dopaminergic drug (droperidol), 
three drug-like agents (oleandrin, navitoclax and AT9283) 
and four other chemical entities (endothal, endosulfan, 
4-nonyphenol and pseudobaptogenin). We did not identify 
any exclusive or overrepresented targets in the list of the 
eight compounds in comparison to all the compounds 
tested. 
treatment with bcL-2 inhibitors has opposite 
effects under EWs-FLI1-high and -low 
conditions
Among the small number of compounds that 
exhibited higher efficacy in EWS-FLI1-low as compared 
to EWS-FLI1-high EwS cells, was the BCL-2 family 
inhibitor navitoclax (ABT-263). Interestingly, navitoclax 
showed an inverse effect to the pan-BCL-2 family 
inhibitor obatoclax (GX15-070), which is more potent in 
EWS-FLI1-high EwS cells. Thus, we decided to use the 
differential activity of the two BCL2 family inhibitors as 
a model to validate our in silico approach. Cell viability 
in EWS-FLI1-high and -low EwS cells was measured 
after 72 hours of drug treatment using CellTiter Glo. As 
demonstrated by our in silico analysis we were able to 
confirm a strong increase in sensitivity of EWS-FLI1-low 
cells as compared to EWS-FLI1-high cells to navitoclax 
treatment (Figure 3A). The response of EWS-FLI1-high 
and -low EwS cells to treatment with obatoclax was 
comparable, in line with the in silico analysis, with a slight 
increase in EWS-FLI1-high cells. Next, we confirmed that 
the loss of tumor cell viability in response to navitoclax 
and obatoclax treatment was due to apoptosis (Figure 3B). 
While both EWS-FLI1-high and -low cells became 
apoptotic upon treatment with obatoclax, treatment with 
navitoclax led to significantly increased apoptosis in 
EWS-FLI1-low as compared to EWS-FLI1-high cells. 
Similar to A673/TR/sh and parental A673 cells, 
RDES EwS cells used for validation were sensitive to 
treatment with the pan-BCL-2 inhibitor obatoclax, but 
resistant to navitoclax (Figure 3C). Conversely, when we 
compared potencies of the two BCL-2 inhibitors in EWS-
FLI1 negative cancer cells, U2OS osteosarcoma and 
KBM7 chronic myeloid leukemia cell lines, we observed 
markedly different patterns than in EwS. In contrast to 
A673 and RDES, in U2OS navitoclax was dramatically 
more potent than obatoclax, while in KBM7 cells the 
responses to the two drugs were almost identical (Figure 
3C). Navitoclax shares its target spectrum with another 
BCL-2 small molecule inhibitor, ABT-737 [8, 21]. 
Consistently, ABT-737 showed a comparable effectiveness 
in EWS-FLI1-low cells, while EWS-FLI1-high cells were 
resistant to treatment with ABT-737 (Supplementary 
Figure 1C). In U2OS, both navitoclax and ABT-737 
were more potent at inducing cell death than obatoclax 
(Supplementary Figure 1D).
EWs-FLI1 differentially regulates members of 
the bcL-2 family
Next, we studied the mechanism behind the 
EWS-FLI1 dependent differential response to the tested 
BCL-2 family inhibitors. Although the target profiles of 
obatoclax and navitoclax were similar, affinities and the 
selectivity for the anti-apoptotic BCL-2 family members 
differed dramatically [22]. Navitoclax, like ABT-737, 
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Figure 2: compound-target interaction network. (A) Biological processes significantly associated with the exclusive and enriched 
targets of the potent compounds in EWS-FLI1 high EwS cells. Color scale represents the Benjamini-Hochberg adjusted p-value while the 
circle size is analogous to the number of genes found to be involved in the corresponding terms. Histone deacetylase activity, apoptosis, 
ribosome biogenesis and topoisomerase activity were among the top processes affected. (b) Interactions between potent compounds (blue 
diamonds) and genes, which were found to be exclusively targeted (purple nodes) or enriched in the list of potent compounds (cyan nodes) 
in EWS-FLI1-high EwS cells. Genes which increased or decreased in expression upon EWS-FLI1 knockdown (RNA-seq data derived by 
[10]) are highlighted with red and green halos, respectively. Color intensity indicates degree of regulation. Potential EWS-FLI1 targets 
according to Chip-seq data derived by [18] are indicated with bold black text.
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shows strong affinity for BCL-2, BCL-X(L), and BCL-W, 
while they are inactive towards MCL-1 and BCL-B. In 
contrast, obatoclax targets all BCL-2 family members 
with similar affinity [22], however, with weaker potency 
than navitoclax. Next, we tested inhibitors of BCL2, 
BCL-X(L), and MCL-1 (ABT-199, A-1155463, S63845, 
respectively). We observed that curve shifts depicting 
difference in viability between EWS-FLI1-high and 
-low states upon treatment with either BCL-2 or BCL-
X(L) inhibitor resemble the pattern of navitoclax (higher 
Figure 3: differential effect of navitoclax and obatoclax on EWs-FLI1-high and -low Ews cells. (A) Dose response 
curves of obatoclax and navitoclax in EWS-FLI1 high and low conditions. (b) A673/TR/shEF cells were treated with dox for 96 h in total. 
Navitoclax (3.5 µM) and obatoclax (100 nM) were applied for 72 h. DMSO was used as control. AnnexinV staining was performed, the 
percentage of apoptotic cells determined, normalized to DMSO control and displayed as relative fold change. Data are shown as means ± 
SD from 4 independent experiments. (*p < 0.05, **p < 0.01, ***p < 0.001 - compared to DMSO; #p < 0.05, ##p < 0.01, ###p < 0.001 NVX 
treatment compared in EWS-FLI1 expressing versus EWS-FLI1 knockdown cells.) NVX, navitoclax; OBX, obatoclax. (c) Upper panel: 
comparison of the effect between navitoclax and obatoclax in two EwS cell lines (A673 and RDES); lower panel: potency of navitoclax and 
obatoclax in two non-EwS cell lines (U2OS and KBM7). The pattern of sensitivity for the two drugs was found to be similar in the EwS 
cell lines, while it differed in the non-EwS cell lines.
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potency in EWS-FLI1-low state), while in contrast the 
MCL-1 inhibitor was more potent in EWS-FLI1-high 
state, thus belonging to the larger group of compounds 
with higher efficacy in EWS-FLI1-high condition 
(Supplementary Figure 2). Although the shifts are mild, 
they are in concordance with reported targets of navitoclax 
and obatoclax and with the phonotypes that we observed.
Since RNA expression data in several EwS cell lines 
suggested EWS-FLI1-dependent regulation of MCL-1 
expression [10, 23] we hypothesized that MCL-1 levels 
could explain the differential navitoclax sensitivity in 
EWS-FLI1-high and -low conditions. Using immunoblot 
we confirmed a decrease in MCL-1 protein expression 
upon dox-induced knockdown of EWS-FLI1 in A673/TR/
shEF cells (Figure 4A and 4C). Interestingly, treatment 
with navitoclax increased MCL-1 expression levels 
strongly in the EWS-FLI1-high, but not -low state (Figure 
4A). Upregulation of MCL-1 expression upon treatment 
with navitoclax or ABT737 has been previously reported 
as a mechanism of resistance in various cancer cells 
[9, 24]. To test whether a decrease in MCL-1 expression 
enhances sensitivity to navitoclax in EWS-FLI1-high EwS 
cells, we performed a transient knockdown of MCL-1 
using siRNA. Strikingly, knockdown of MCL-1 (Figure 
4B) led to a similar drug effect on EwS cell viability as the 
knockdown of EWS-FLI1 in the A673/TR/shEF system. 
While no changes in sensitivity towards obatoclax were 
observed, a large shift towards improved sensitivity was 
noted upon navitoclax treatment. EWS-FLI1 knockdown 
strongly reduced MCL-1 protein expression (60% 
reduction) (Figure 4A and 4C), while levels of anti-
apoptotic proteins BCL-2 and BCL-X(L) were decreased 
and increased by 50%, respectively (Figure 4C). We also 
observed sequestration of MCL-1 to nuclear speckles in 
the EWS-FLI1-low state, as compared to EWS-FLI1-
high (Figure 4D). This pattern is highly reminiscent 
of the product of the immediate early gene X1 (IEX-1/
IER3), which was previously reported to sequester MCL-
1 in response to DNA damage [25], at least partially co-
localizing with PML bodies in HeLa cervical carcinoma 
cells [26]. In this cell line, upregulation of IER3 was 
required for DNA damage to induce apoptosis [27]. 
Intriguingly, we found IER3 to be strongly induced 
upon conditional EWS-FLI1 knockdown in A673/TR/
shEF (Figure 4E) and, with the only exception of SK-N-
MC, in four of five additional cell lines upon transient 
knockdown of EWS-FLI1 [23]. Ectopic expression of 
IER3 on its own slightly increased navitoclax sensitivity 
of A673/TR/shEF cells, though the level of this increase 
did not achieve significance (Supplementary Figure 3). 
Thus, it is conceivable that a combination of MCL-1 
expression modulation and IER3 dependent subcellular 
re-localization in response to EWS-FLI1 depletion is 
contributing to the observed gain in navitoclax sensitivity, 
suggesting a major role for MCL-1 in apoptosis regulation 
and navitoclax resistance of EwS. 
In the next step we used the near-haploid KBM7 
cell line [28] to further investigate the mode of action 
of BCL-2 inhibitors. Anti-apoptotic BCL-2 proteins 
function by segregating particular BH3 proteins. Caused 
by apoptotic stimuli, BH3 sensitizers such as NOXA or 
BAD liberate the so-called BH3 activators, allowing them 
to activate membrane permeabilizing proteins BAK and 
BAX which oligomerize [22, 29], ultimately leading to 
apoptosis. Thus, pro-apoptotic BH3-only members BAX 
and NOXA are crucial for the classical intrinsic apoptosis 
pathway that is regulated by pro- and anti-apoptotic BCL-
2 family proteins. Isogenic knockout systems for BAX and 
NOXA in the KBM7 cell line confirmed different modes 
of action of navitoclax and obatoclax. While the potency 
of navitoclax decreased in the absence of either BAX or 
NOXA, obatoclax remained equally potent, indicating a 
distinct mechanism of action (Supplementary Figure 4). 
dIscussIon
We have developed and applied a network-based 
systems biology approach to investigate aspects of EWS-
FLI1 function in the pathogenesis of EwS and identify 
compounds interfering with EWS-FLI1 driven cell 
viability. 
By performing high-throughput perturbation screens 
with more than 3000 compounds in an EwS model cell line 
upon conditional EWS-FLI1 expression (EWS-FLI1-high 
versus -low), we unraveled novel EWS-FLI1-dependent 
vulnerabilities. Integrative network analysis of EWS-FLI1 
target spectra revealed crucial cellular processes affected, 
such as translation, histone deacetylation, topoisomerase 
activity and microtubule organization. We identified 70 
compounds with enhanced efficacy exclusively upon 
high EWS-FLI1 expression. Apart from compounds 
already included in the backbone of EwS standard 
therapy protocols (vincristine, doxorubicin) or used in 
the treatment of refractory disease (e.g. topotecan [30] 
and irinotecan [31]), we identified novel targeted small 
molecules which are either used in the treatment of other 
cancer types, such are obatoclax and belinostat, or already 
in early clinical development for pediatric indications and 
therefore hold promise for future use in the treatment of 
Ewing sarcoma. Among them taxol (paclitaxel) is currently 
in Phase 1 and 2 clinical trials for several pediatric 
malignancies. Importantly, it is in a Phase 2 for Ewing 
Sarcoma (NCT01962103). It is a microtubule-stabilizing 
drug, but interestingly it also induces apoptosis by binding 
to and blocking the function of the apoptosis inhibitor 
protein BCL-2. Topotecan, a semi-synthetic derivative of 
camptothecin, is a topoisomerase-I inhibitor currently in 
several pediatric clinical trials, where its efficacy is tested 
in combination with a number of chemotherapeutics. 
Oncotarget31025www.oncotarget.com
Figure 4: McL-1 expression levels are EWs-FLI1 dependent and contribute to the drug-induced phenotype. (A) 
Immunoblot showing MCL-1 expression upon navitoclax (NVX; 3.5 µM) treatment in A673/TR/shEF. Expression levels of MCL-1 
are increased by NVX, unless EWS-FLI1 levels are low (dox). Blot shows quantification of MCL-1 fold change expression relative to 
GAPDH of two independent experiments. (b) Left, knockdown efficiency of MCL-1 upon transcfection with si-MCL-1 or si-control in 
A673/TR/shEF cells. Right, dose response curves of obatoclax and navitoclax in si-control transfected A673/TR/shEF cell line and upon 
knockdown of MCL-1. (c) Immunoblot image of MCL-1 (L), BCL-X (L) and BCL-2 expression changes upon dox-induced EWS-FLI1 
knockdown in A673/TR/shEF EwS cells (48 h and 72 h timepoints) (left) and quantification of protein expression relative to α-TUBULIN 
from three independent experiments (mean ± SD). P-values were calculated using One-Sample T-Test comparing expression changes 
after dox treatment to the untreated control (*=≤0.05; **=≤0.01; ***=≤0.001) (right). (d) Subcellular localization of MCL-1 is shown with 
immunofluorescence confocal microscopy at 63X magnification, demonstrating the appearance of MCL-1 in nuclear speckles (indicated 
with arrows) in EWS-FLI1-low cells (dox). One representative experiment from three biological replicates is shown. (E) Protein expression 
of IER3 (IEX1) is highly upregulated in EWS-FLI1-low cells (72 h dox) as shown by western blot. Respective quantification of IER3 bands 
from three independent experiments was performed by normalization to GAPDH.
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Gemcitabine, an antimetabolite nucleoside, is also 
already in clinical trials for pediatric application. It is 
tested with taxol in pediatric non-central nervous system 
(CNS) solid tumors (NCT03507491). Bortezomib, a 
proteasome inhibitor, is tested in combination with the 
HDAC inhibitor vorinostat to treat different types of 
solid tumors in children (NCT01132911). Mebendazole is 
already approved to treat parasitic infections. It is in Phase 
1 trial for recurrent pediatric brain cancers that include 
medulloblastoma and high-grade glioma refractory to 
standard-of-care therapies (NCT026442919). The HDAC 
inhibitor Vorinostat (SAHA), although so far only FDA 
approved for cancer treatment in adults but not yet in 
children, is in several clinical trials for pediatric patients 
for example in combination with bortezomib (Phase 1, 
NCT01132911) or lenalidomide (Phase 1, NCT03050450) 
for the treatment of high grade or progressive central 
nervous system tumors, and with etoposide (Phase 2, 
NCT01294670) for relapsed and treatment refractory 
sarcomas.
While apoptotic pathways are successfully targeted 
in multiple cancers, in EwS the cross talk between EWS-
FLI1 and apoptosis is less studied. It has been reported 
that protection from DNA-damage induced apoptosis by 
EWS-FLI1 and FLI1 involves recruitment of the CBP/
P300 coactivator in a transcription independent way 
[32]. Other studies suggested that EWS-FLI1 binds to the 
anti-apoptotic protein BCL-2 [33]. Most recently, it was 
reported that malignant transformation of bone progenitor 
cells in a transgenic EWS-FLI1 mouse model required 
expression of MCL1 or other anti-apoptotic BCL-2 family 
members [34]. Zöllner et al. reported that treatment of 
EwS cells with the EWS-FLI1 inhibiting molecule YK-
4-279 induces cell cycle arrest but furthermore supports 
apoptosis via decreasing anti-apoptotic MCL-1(L) and 
increasing the pro-apoptotic isoforms of MCL-1(S) and 
BCL-2 [7]. Our results show that EWS-FLI1 expression 
potentiates the inhibitory effect of agents like cytarabine, 
bortezomib and gambogic acid. Most of them induce 
sensitivity in EwS cells likely through targeting different 
members of the BCL-2 family. Two well established 
BCL-2 family inhibitors (obatoclax and navitoclax) were 
found to have dramatically different effects dependent on 
EWS-FLI1, suggesting a cross talk between EWS-FLI1 
and specific members of the apoptosis regulatory family 
that are differentially targeted by both drugs. Here, we 
demonstrate that this crosstalk is mediated via EWS-FLI1 
dependent MCL-1 protein expression and conceivably 
also subcellular re-localization of MCL-1. Our previous 
ChIP-seq studies identified EWS-FLI1 binding to the 
MCL-1 promoter [10, 18]. Additionally, we observed that 
knockdown of EWS-FLI1 greatly reduces the expression 
of MCL-1, identifying this BCL-2 family member as a 
directly EWS-FLI1 activated target. We found that EWS-
FLI1 modulation results in upregulation of IER3, which 
was previously reported to be responsible for MCL-1 
translocation to nuclear speckles [25]. The appearance 
of MCL-1 in nuclear speckles was also observed in our 
EwS model cell line upon knockdown of EWS-FLI1. In 
293T cells, IER3 ectopic expression induced apoptosis in 
an MCL-1 and BIM1 dependent but NOXA and PUMA 
independent manner [35]. In our study, we found that 
upregulation of IER3 alone is not sufficient to explain 
the dramatic gain in navitoclax sensitivity of EwS under 
EWS-FLI1 low conditions. However, the combination of 
dampened MCL-1 expression with its altered subcellular 
localization largely contributes to the apoptotic response 
to this drug. 
To test dependency on individual BCL-2 family 
members we used siRNA pools and against BCL2, BCL-
X(L), and MCL-1 individually and in combination for their 
influence on viability in A673/TR/sh cells under EWS-
FLI1-high and -low conditions (Supplementary Figure 5). 
They show that genetically inhibiting each of the BCL2 
family members individually and in combination results 
in decreased EwS viability confirming the importance of 
these molecules for EwS pathogenesis. 
It should be noted that, with regard to navitoclax 
sensitivity, SK-N-MC EwS cells behaved differently 
from all other EwS cell lines tested. Modulating EWS-
FLI1 expression in a dox-inducible EWS-FLI1 shRNA 
expressing clone of that cell line, shSK-E17T, failed to 
induce navitoclax sensitivity (Supplementary Figure 6A). 
Consistent with this finding, EWS-FLI1 knockdown did 
not reduce MCL-1 nor increase IER3 expression levels 
(Supplementary Figure 6A and 6B). 
Experiments in isogenic near-haploid cell lines 
lacking different pro-apoptotic BH3-only BCL-2 family 
members showed that navitoclax activity requires the 
expression of NOXA or BAX, which was not the case 
for obatoclax. These findings in EwS cells are consistent 
with previous results obtained in leukemic cells, where 
resistance to the navitoclax related BCL-2 inhibitor 
ABT-737 was demonstrated to be dependent on MCL-1 
phosphorylation [36]. Interestingly, it has been reported 
that the resistance towards ABT-737 could be overcome 
by increased expression of NOXA, identifying NOXA 
and MCL-1 as determinants for cell death in ABT-737-
resistant cells caused by gossypol, another BCL-2 inhibitor 
targeting MCL-1 [37]. Although all our data point to 
an important role of MCL-1 in differential sensitivities 
of EwS cell lines towards the two BCL-2 inhibitors, it 
cannot be excluded that additional, so far unknown, targets 
of obatoclax may also be involved. The targets may not 
necessarily be related to the inhibition of BCL-2 pro-
apoptotic proteins or interfering with intrinsic apoptosis 
pathways [38–40]. 
In conclusion, our integrative drug screening 
analysis methodology in EwS confirmed known EWS-
FLI1 interfering mechanisms and discovered novel ones. 
Moreover, we present a collection of promising small 
molecule candidates for further pre-clinical development 
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in EwS. The vulnerable EwS biological processes 
identified in this study provide a basis for future functional 
investigations and drug synergy screens. In addition, we 
provide a list of compounds not effective in any of the 
conditions tested but also a list of compounds effective 
in both EWS-FLI1-high and -low cells that could inform 
and accelerate the progress of future EwS therapeutic 
strategies. Our systems biology approach can be extended 
and applied in a variety of large-scale compound screen 
studies tested for multiple conditions and diseases 
to enable identification of potential drug targets and 
understand their mechanism of action.
MAtErIALs And MEtHods
cell lines and cell culture
All cell lines used in this study are STR authenticated 
and regularly tested for absence of mycoplasma infections 
(Mykoalert kit, Lonza, Basel, Switzerland). The EwS model 
cell line A673/TR/shEF [41] was grown in DMEM (high 
glucose 4.5 g/l + GlutaMAX, Gibco, Waltham MA USA) 
supplemented with 10% Tet system Approved Fetal Bovine 
Serum (Clontech, penicillin and streptomycin, 50 µg/
ml Zeocin (Invitrogen, Thermo Fisher; Waltham, MA, 
USA) and 2 µg/ml blasticidine S hydrochloride (Sigma-
Aldrich; St. Louis, MO, USA). To induce the expression 
of the EWS-FLI1 shRNA, cells were exposed to 1 µg/ml 
doxycyline (Sigma-Aldrich; St. Louis, MO, USA) for 
72 hours. Drug screens in this cell line were initiated 24 h 
after dox-induced shRNA induction. 
The shSKE-17T cell line, a clone of the SK-N-MC 
EwS cell line with dox-inducible EWS-FLI1 shRNA 
expression, was kindly provided by O. Delattre (Institut 
Curie, Paris, France) [20]. For the dose-response curves 
shown in Supplementary Figure 5, cells were treated for 
48 h with dox (1 µg/ml) to induce EWS-FLI1 knockdown 
and then were treated with Navitoclax (3.5 µM) for 72 h 
in the presence or absence of dox. Cell lines A673, RDES 
and U2OS were purchased from the American Type 
Culture Collection (ATCC). KBM7 cells were grown in 
Iscove’s modified Dulbecco’s medium (IMDM) with 10% 
fetal calf serum (FCS). BAX and NOXA knockout cell 
lines were obtained from Haplogen GmbH, where a gene-
trap retrovirus was used to inactivate single human genes 
in KBM7 as described previously [28].
transfections and plasmids
To achieve efficient knockdown of MCL-1 (see 
Figure 4B) a siRNA Smart Pool from Dharmacon (L-
004501-00-0005, Dharmacon; Lafayette, CO, USA) was 
used together with INTERFERin (Polyplus, Illkirch, France) 
transfection reagent, according to manufacturer instructions. 
Other transfections with siRNA were carried out 
using Oligofectamine reagent (Invitrogen, Groningen, 
the Netherlands) according to the manufacturer’s 
instructions. Knockdown of BCL-2, BCL-X(L) and 
MCL1 (see Supplementary Figure 2) was achieved by 
using MISSION® esiRNAs from Sigma-Aldrich (Vienna, 
Austria); esiRLUC was used as a non-targeting control 
and esiKIF11 as a positive control, as suggested by the 
manufacturer.
For ectopic overexpression of IER3 (IEX1), 
the IER3 expression vector and control vector (Iex1-
pcDNA3.1 and pcDNA3.1, respectively, supplied by Prof. 
Heiner Schäfer, Laboratory of Molecular Gastroenterology 
and Hepatology, Universitätsklinikum Schleswig-Holstein, 
Kiel, Germany) were employed. Briefly, using the dox-
inducible A673/TR/shEF cell line [41], transfections 
were performed with the Lipofectamine-Plus reagent 
(Invitrogen, Groningen, the Netherlands) according to the 
manufacturer’s recommendations. EWS-FLI1 knockdown 
and cell viability determinations were done as previously 
reported [42]. Transfections were carried out using 
Lipofectamine Plus reagent (Invitrogen, Groningen, the 
Netherlands).
High-throughput cell viability screens
Before performing the high-throughput compound 
screening, cell number was titrated to ensure that cell 
proliferation remained in a linear exponential phase 
throughout the experiment. The screens were performed in 
384-well format using plates containing compound stock 
solutions, or DMSO as controls. 1,500 cells per well were 
seeded in 40 µl of culture medium both with and without 
dox to maintain EWS-FLI1 shRNA expression throughout 
the screen. The high-throughput compound screen was 
performed in three parts summarized in Table 1. First, 
kinase and phosphatase inhibitors present in the Biomol 
International compound library (Biomol international; 
L.P. PA, USA) and Multisource Spectrum compounds 
(MicroSource Discovery Systems, Inc.; Gaylordsville, 
CT, USA) consisting of known drugs, other bioavailable 
compounds and natural products were screened. The 
second screen comprised MicroSource Cancer drugs 
and a LOPAC compound library (Sigma-Aldrich; St. 
Louis, MO, USA) consisting of FDA approved drugs 
and other compounds with pharmacologically relevant 
structures. Third, Selleck compound library (Selleckchem 
Chemicals; Houston, TX, USA) containing FDA approved 
drugs and additional experimental compounds were 
used. All compounds were tested in at least two different 
concentrations. Cell viability was measured after three-
day incubation with compounds using CellTiter-Glo 
(CTG) cell viability assay (Promega; Madison, WI, 
USA) with Envision Plate-reader (PerkinElmer/Wallac; 
Waltham, MA, USA) according to manufacturer’s 
instructions. The raw results were normalized using the 
LOESS-log normalization algorithm as implemented in R 
(http://www.r-project.org/). The method down-weights 
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outliers on the plate before calculating the LOESS fit. 
The Loess-fit approach was chosen to be used in this 
study as it enables discovery of areas on plates where 
signal intensities are systematically higher or lower than 
the signals in adjacent wells on a plate. After LOESS 
correction, data was divided by the median of negative 
controls and log2-transformed. For each screen, the 
compounds that were qualified as hits, were the compounds 
that inhibited cell viability by at least three median absolute 
deviations (MADs) from the median of all screened wells. 
To consider that a compound presents increased effect upon 
high or low EWS-FLI1, we required that there is at least 
two-fold decrease in the cell viability upon high EWS-FLI1 
compared to low EWS-FLI1 and vice versa.
compound protein interaction data 
preprocessing and integration
All compounds tested were cross referenced 
with their respective PubChem identifier [43] to avoid 
ambiguities caused by synonyms used in the different 
compound libraries. To obtain information on drugs and 
their targets, we combined data from the publicly available 
resources ChEMBL version 19 [13] and STITCH version 
9.0 [14]. The raw data from ChEMBL were filtered to 
remove possibly erroneous entries. The filtering pipeline 
included removing all data without supporting references, 
as well as records with missing values, protein names 
or measurement units. Further, we selected only records 
with half maximal inhibitory concentration (IC50) or 
inhibition constant (ki) measurement units below 1 µM on 
targeting human proteins. In addition, ChEMBL assigns a 
confidence score to all entries, indicating the experimental 
source supporting each entry. We included only data 
assigned with a confidence score of four or higher (nine is 
the highest), which indicates a biochemical measurement. 
The information retrieved from STITCH was derived from 
the “experimental” and “databases” evidence channels. 
Only data with a STITCH confidence score equal or above 
0.8 were included. Additional manual literature curation 
was performed for the compounds showing effect. Out of 
the 3,325 compounds tested we were able to retrieve target 
information for 1,515 compounds.
Protein functionality analysis
To investigate processes affected by the compounds 
of interest, we focused on genes that are exclusive 
targets or overrepresented in the above compound set. 
Overrepresented targets were defined using the Fisher’s 
exact test and false discovery rate (FDR) adjusted p-value 
threshold of 0.05. To investigate potentially affected 
functions reflected by the above genes we used the Gene 
Enrichment and Functional Annotation tool provided by 
the DAVID toolkit [15]. The tool implements a modified 
Fisher’s exact test to determine genes falling into the 
same functional categories according to their assigned 
functional ontology terms. We selected to create the sets of 
potentially functionally related genes, on terms derived by 
the Gene Ontology “biological process” and “molecular 
function” information channels [16] as well as the KEGG 
pathway database [17]. The default parameters were used, 
with Benjamin-Hochberg p-value adjustment (q-value) 
threshold of 0.01. 
network construction
The protein interaction network was obtained by 
using the STRING v9.1 database [44]. To ensure high 
confidence interactions only, protein interactions assigned 
as experimentally verified were retrieved and a confidence 
score above 0.8 was required. Network visualization was 
performed using the Cytoscape platform v3.2.0. 
Proliferation assays
The individual drug effects were determined in 
proliferation assays using Cell Titer Glo (Promega Inc., 
Madison WI, USA) as the readout. Cells were plated in 
96-well plates and treated with drugs the following day. 
Serial dilutions in a range between 20 µM and 0.05 µM 
were applied for 72 h. In the case where the knockdown 
of EWS-FLI1 was induced, the induction with dox started 
24 h prior to the drug treatment and the cells were kept 
in dox during the drug treatment. IC50 values were 
determined by fitting a dose response curve to the data 
points using non-linear regression analysis utilizing the 
table 1: summary of compound screens performed in EWs-FLI1-high and -low A673/tr/shEF Ewing sarcoma 
(Ews) cells
screen compound library compounds Final concentrations
1
 
Multisource Spectrum 2000 2.5 µM, 250 nM
Biomol International 84 25 µM, 2.5 µM, 250 nM, 25 nM
2
 
Sigma LOPAC 1280 2.5 µM, 250 nM
Microsource Cancer 80 25 µM, 2.5 µM, 250 nM, 25 nM
3 Selleck 522 25 µM, 8.3 µM, 2.8 µM, 926 nM, 308 
nM, 103 nM
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GraphPad Prism software (GraphPad Software, Inc, La 
Jolla, CA, USA).
Apoptosis analysis by annexinV staining
To examine the effects of navitoclax and obatoclax 
on cell death, the number of dead and apoptotic cells 
was measured by flow cytometry analysis after 72 h 
inhibitor treatment. Adherent and floating cells were 
analyzed with the AnnexinV Apoptosis Detection Kit 
APC (eBioscience, San Diego, USA). AnnexinV and 
DAPI (Sigma-Aldrich) staining were performed according 
to manufacturer’s instructions and FACS Fortessa and 
Diva™ (BD Biosciences, CA, USA) software were used 
for quantification purposes. As positive control, apoptosis 
was induced via camptothecin (1 µM) for 48 h. Data 
were analyzed using the unpaired t-test with Welch’s 
correction or with the one-sample t-test using the Prism 5 
for Windows (version 5.02) statistical software (GraphPad 
Prism Software Inc.).
Immunofluorescence and immunoblot analyses
For immunofluorescence microscopy, cells were 
fixed with 4% para-formaldehyde (PFA) in phosphate 
buffered saline (PBS) for ten minutes at room temperature. 
Cells were permeabilized with 0.3%Triton-X in PBS with 
addition of 5% goat serum (Dako, Vienna, Austria) for 
30 minutes at room temperature. Subsequently, the primary 
rabbit-MCL-1 (ab32087, Abcam, Cambridge, UK) was 
added at 1:400 dilution in 0.1%Triton-X/1% bovine serum 
albumin (BSA)-PBS with 1% goat serum over night at 4° 
C. The secondary goat-anti rabbit Alexa Fluor 488 antibody 
(A11034, Life Technologies, Sigma-Aldrich) was diluted 
in 0.1%Triton-X in 2%BSA-PBS with 1% goat serum and 
added for 30 minutes at room temperature. Cells were 
mounted with Vectashield mounting medium containing 
DAPI (Vectorlabs, Peterborough, UK). Immunostainings 
were visualized at 63× magnification using the Leica TCS 
SP8 confocal microscope and images were taken using the 
Leica LAS-AF software (Leica, Wetzlar, Germany).
For immunoblot analysis, total proteins were 
resolved by 10% or 12.5% SDS-polyacrylamide gel 
electrophoresis and processed for immunoblotting. 
Antibodies used were against MCL-1 (#4572, Cell 
Signaling, New England Biolabs, Frankfurt am Main, 
Germany), BCL-X(L) (ab178844, Abcam, Cambridge, 
MA, USA), BCL-2 (ab18210, Abcam), BCL-2 (ab18210, 
Abcam, Cambridge, MA, USA) IEX-1/IER3 (sc-8454, 
Santa Cruz, Santa Cruz, CA, USA), FLI1 (MBS177100, 
My Biosource, San Diego, CA, USA), α-TUBULIN 
(CP06, Calbiochem, Merck, Vienna, Austria), GAPDH 
(AM4300, Ambion, Thermo Fisher Scientific). Linear 
protein quantification was performed using the LICOR 
Odyssey® Infrared Imaging System and ImageJ 
software [45]. 
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